Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: Treatment
Information Summaries from PDQ
Drugs Approved for Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for ovarian cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.
MEK: A Single Drug Target Shows Promise in Multiple Cancers
Drugs that block the MEK protein have shown promise in several cancers. Trametinib has had encouraging results in patients with advanced melanoma, and selumetinib has been tested in patients with advanced thyroid and ovarian cancers.
Combining Chemotherapy with Bevacizumab Improves Outcomes for Ovarian Cancer Patients
Results from two phase III randomized clinical trials suggest that, at least for some patients with ovarian cancer, adding the antiangiogenesis agent bevacizumab to chemotherapy increases the time to disease progression and may improve survival.
Related Treatment Information
A fact sheet that describes the process of eliminating the blood supply to tumors. Lists the cancers in which this approach is being tested.
Biological Therapies for Cancer
A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies, such as monoclonal antibodies, cytokines, therapeutic vaccines, the bacterium bacillus Calmet-Guérin, cancer-killing viruses, gene therapy, and adoptive T-cell transfer.
Targeted Cancer Therapies
A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival.
A fact sheet about metastasis, the spread of cancer to other parts of the body. Discusses the diagnosis and treatment of cancer that has spread.